§ 01 · Source
“Bottom 20% by income die 9 years earlier than the top 20%.”
NCOA / UMass Boston2024
§ 01 · The gap
Two enormous categories, never once connected.
The wearables market and the longevity economy have been growing in parallel for a decade. Nobody has linked daily wearable behavior to real recurring income. That is the gap Wellex was built to close.
§ 02 · Source
“Health-wealth gap reaches 10–15 years.”
Vanderbilt University Medical Center2024
§ 03 · Source
“Gap grew from 12.6 to 20.4 years between 2000 and 2021.”
The Lancet2024
§ 02 · The market stack
Eight numbers that define the category.
Verified in Brand Bible v3 Appendix A. Sources are cited on each cell so the underwriting conversation is fast.
$0B → $185B
Wearable technology market
Wissen Research · 2025 · CAGR 15%
$0B → $168B
Wearable medical devices
Grand View Research · 2025 · CAGR 25.5%
$0B → $44B
Longevity clinical market
DataM Intelligence · 2025 · CAGR 7.8%
$0B+ → $8T
Longevity economy
Oliver Wyman / Aranca · 2025
$0B
Longevity + preventive wellness
Global Insight Services · 2025
$0.0B
Longevity VC 2024 (+220% YoY)
Longevity.Technology · 2025
~0M
Wearables sold in 2024
IDC Worldwide Wearables Tracker · 2025
§ 03 · Why Wellex wins the category
Four structural advantages, one honest moat.
Each of these was an architectural decision before it was a marketing line. The four cards below are the same four we use in the investor deck — nothing is dressed up for the page.
§ 01
0position
First-mover in L2E
The Live to Earn category did not exist before Wellex. We define it, we own the URL, and we ship the product that teaches the category what good looks like.
§ 02
0tokens
Zero token risk
No token has ever been issued. No token will ever be issued. Yield comes from real multi-chain staking paid in USDT. The entire regulatory surface is wellness hardware plus a SaaS subscription.
§ 03
0gross %
Recurring + yield fee
Two revenue lines. Nineteen-dollar subscription is company revenue. A percentage of the yield is company revenue. Partner bonuses come from yield only — never from subscription.
§ 04
0reach %
Global by default
The bracelet ships to any address. The app runs in any locale. The yield rail runs on every EVM chain and Tron today, Solana on the roadmap. No country-specific regulatory dependency.
§ 04 · Monetisation streams
Five streams. Two of them already live.
Core is live. Secured is contracted. Roadmap is intentional — published so there is no confusion about what we are selling today versus what we are selling in eighteen months.
Description
Status
$19/mo subscription
Primary revenue stream. AI, monitoring, recommendations.
Core · live
Yield commission
Wellex takes % from multi-chain staking yield.
Core · live
Partner bonuses
Bonuses to affiliates from yield, not from subscription.
Secured
Premium plan
Extended analytics, AI coach, telemedicine.
Roadmap
B2B / Corporate wellness
Wellness programs for companies.
Roadmap
| Stream | Description | Status |
|---|---|---|
| $19/mo subscription | Primary revenue stream. AI, monitoring, recommendations. | Core · live |
| Yield commission | Wellex takes % from multi-chain staking yield. | Core · live |
| Partner bonuses | Bonuses to affiliates from yield, not from subscription. | Secured |
| Premium plan | Extended analytics, AI coach, telemedicine. | Roadmap |
| B2B / Corporate wellness | Wellness programs for companies. | Roadmap |
§ 05 · Competitive matrix
Seven rows. Wellex is the only column with every check.
Apple Watch, Oura, Whoop, longevity clinics, Wellex. The same seven criteria, one honest answer per row. The highlighted column is ours because this is our page.
Apple Watch
Oura
Whoop
Clinics
Wellex
Health monitoring
✓
✓
✓
✓
✓
Passive income
✗
✗
✗
✗
✓ real yield
Longevity focus
✗
partial
✗
✓
✓
Accessible price
from $399
from $299
from $228
from $10K/yr
From $49
AI personalisation
basic
basic
basic
✓
✓
No tokens
✓
✓
✓
✓
✓
Physical device
✓
✓
✓
✗
✓
| Criterion | Apple Watch | Oura | Whoop | Clinics | Wellex |
|---|---|---|---|---|---|
| Health monitoring | ✓ | ✓ | ✓ | ✓ | ✓ |
| Passive income | ✗ | ✗ | ✗ | ✗ | ✓ real yield |
| Longevity focus | ✗ | partial | ✗ | ✓ | ✓ |
| Accessible price | from $399 | from $299 | from $228 | from $10K/yr | From $49 |
| AI personalisation | basic | basic | basic | ✓ | ✓ |
| No tokens | ✓ | ✓ | ✓ | ✓ | ✓ |
| Physical device | ✓ | ✓ | ✓ | ✗ | ✓ |
§ 06 · Risk disclosure
Six risks. Six written mitigations.
We publish the risk list because the only thing worse than an honest risk is a hidden one. Likelihoods are from Brand Bible v3 section XIX and update quarterly.
§ 01
highHardware delays — bracelet in development
White-label OEM partnership (Realme / Amazfit). MVP via existing hardware + custom software.
§ 02
mediumYield depends on multi-chain staking
Diversified yield sources. Transparent APY communication.
§ 03
mediumRegulatory — wellness vs medical device
Positioned as wellness device. Legal disclaimers. Regulatory consultants.
§ 04
high'Longevity' not directly provable
Language: 'technologies associated with longevity'. References, not promises.
§ 05
lowCompetition — Apple/Samsung could add yield
First-mover advantage in L2E. Apple won't touch yield due to regulatory risks.
§ 06
mediumAffiliate → negative media perception
Clear differentiation: no mandatory purchases, transparent Partner Network.
§ 07 · How an investor benefits
Three ways the category pays back.
One bracelet generates three distinct return curves. None of them require us to invent a token or a new consumer behaviour — only to sell more bracelets and run the yield rail cleanly.
§ 01
0category
Category creation premium
Live to Earn is a new category with a single credible brand inside it. Category-definer multiples have historically compounded faster than incumbent multiples through an entire cycle.
§ 02
0ARPU $
Recurring revenue
Nineteen dollars a month, cancel-anytime, collected in USD. A subscriber who stays twelve months pays for their own acquisition twice over. The curve compounds without a second ad dollar.
§ 03
0APY %
Yield-layer revenue share
A percentage of every USDT payout is company revenue. Yield is paid from real multi-chain staking — more active members means more yield flow, which means more company revenue in the same line item.
§ 08 · Why now
Five conditions just lined up. We did not engineer the timing.
A category-defining bet only works when macro tailwinds arrive together. Five independent signals — regulatory, demographic, technological, capital, behavioural — have moved into the same quadrant within the last twelve months. Wellex is the first product built explicitly to ride them.
- 01Regulatory
Stablecoin clarity in EU (MiCA full enforcement) and US (GENIUS Act path) lets a USDT-only payout layer exist without a token-issuer designation.
MiCA Q4 2025 / GENIUS Act 2025
- 02Demographic
Global 60+ population crossed one billion in 2024 — the same cohort that made longevity-clinic spending grow 22% YoY.
UN World Population Prospects 2024
- 03Technological
Optical-sensor cost dropped 71% since 2019. Continuous biometrics that needed a $5,000 wearable in 2020 fit a $49 retail unit in 2026.
Yole Group Wearable Sensors 2025
- 04Capital
Longevity VC hit $8.5B in 2024 — up 220% — but no fundable startup yet ships hardware that pays the user.
Longevity.Technology Capital Tracker
- 05Behavioural
Consumers under 35 abandon screen-heavy wearables within 6 months at 67% rate. Screen-free, single-score wellness is the open lane.
Mintel Wearables Tracker 2025
§ 09 · Where we actually are
The honest pre-launch picture. Live, in progress, in design.
Investor diligence usually opens with three questions: is the hardware real, is the model designed, is the team accountable. Below — eight markers grouped by status (Live · In progress · In design). Numbers under "Live" are auditable today. Anything under "In progress" or "In design" is a target with a date, not a result.
§ 01
Hardware production
Pre-production
Pilot batch in fabrication · launch volume locked
In progressQ1 2026
§ 02
Yield pool
Pre-launch
Multi-chain custodianship in contracting · TVL accumulates post-launch
In progressLive Q2 2026
§ 03
HRV validation study
In design
Protocol designed against clinical ECG · target r ≥ 0.90
In designQ3 2026
§ 04
Markets at wave 1
7 lanes
DDP shipping plan: UAE, KSA, EU, UK, RU, KZ, TR
In progressLive at hardware ship
§ 05
Smart-contract audit
In review
Independent firm engaged · report and bytecode hash on completion
In progressQ2 2026
§ 06
Insurance posture
Negotiation
Institutional coverage in negotiation · live at first commercial unit
In progressQ2 2026
§ 07
Closed beta interest
Building
Reservations and waitlist open · numbers publish post-launch
LiveLive waitlist
§ 08
Capital posture
Open round
Conversations in progress · soft interest above plan
In progressQ1–Q2 2026
Status codes — Live: auditable today. In progress: contracted or in active execution. In design: protocol fixed, work not yet begun. Updated each quarter.
Next step
The category exists. So does the product.
Request the investor kit or speak to IR directly. Both options are on the same page because both options should be equally easy.